LuminoMark inj. not checked

Hanlim Pharm. Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.”In the company’s words, NCT04606329 on ClinicalTrials.gov
Tested for
Breast Diseases
Main trialPhase 3
“This study is a multicenter, Randomized, Open-label, Parallel, Phase 3 Clinical Trial in 8 weeks for screening, once Investigational product injection, Follow up visit.”In the company’s words, NCT04606329 on ClinicalTrials.gov

Other drugs for Breast Diseases

All 397 drugs for Breast Diseases

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Completed 28 Jan 2021 To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow LuminoMark inj.

Following is part of Solo: you see every change to LuminoMark inj. the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in